Aptuit expands to bring on later-stage capabilities following client demand

By Zachary Brennan

- Last updated on GMT

Aptuit expands to bring on later-stage capabilities following client demand

Related tags Pharmacology High performance liquid chromatography

CDMO (contract development and manufacturing organization) Aptuit is investing in additional scale and capabilities at its Italian site to augment its 1600L scale API capability and to add a commercial GMP license. 

The expansions are centered on formulation development, analytics and clinical manufacturing to serve Phase III clients and those looking toward commercialization. The company’s integrated CMC (chemistry, manufacturing and controls) solutions, which are currently used by many of the top 20 pharma companies, will now be able to produce commercial APIs as well as capsules and tablets at batch sizes in the range of millions, which should be sufficient for Phase III and commercial purposes.

Aptuit is also adding lab scale nanomilling, hot melt extrusion, and spray drying capacity equipment including SEDDS/SMEDDS (Self-microemulsifying drug delivery system) technology.

The company’s solid-state chemistry and analytical functions across its Italy site will also benefit from XRPD (X-Ray Powder Diffraction), new surface area equipment and Z Potential/Dynamic Light Scattering as well as two new HPLC (high performance liquid chromatography) systems.

Johnathan Goldman, CEO of Aptuit, explained to Outsourcing-Pharma.com that the company is seeing a shift in industry where clients are beginning to prefer “this under-one-roof solution, rather than having to get API and drug product from multiple places​” and companies.

We didn’t choose to go into this market, it came to us via existing customers​,” Goldman said, noting that customer demand was the driver of the expansions, which also added an unspecified number of new employees to the Italian facility.

We have now received many requests to support programs to Phase III and beyond NDA (new drug application) filing to product launch.  The expansion of capacity, numerous capital investments and adding GMP license is part of our strategy to leverage our core competency of integrated early Phase CMC to fully integrated CMC at commercial scale. We will deliver these services from our fully integrated CMC facilities in Verona, Italy, and Oxford, UK​,” he added.

Goldman also said the company is expecting to finalize “a couple of acquisitions​” in the coming months, though confidentiality issues stopped him from elaborating more.

Related news

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more